Our current portfolio of products include:

• 
  

  Grafeel®, Dr. Reddy’s filgrastim received its first approval in 2001 and is currently sold in seven countries around the world.

  » Read more
• 
  

  Reditux™, Dr. Reddy’s brand of rituximab received its first approval in 2007, and is currently sold in seven countries, with dossiers under review in several other countries.

  » Read more
• 
  

  Cresp®, Dr. Reddy’s brand of darbepoetin alfa was first launched in 2010 and is currently the only darbepoetin alfa marketed in India.

  » Read more
• 
  

  Peg-grafeel™, Dr. Reddy’s brand of pegfilgrastim was launched in 2011 and is the only single source pegfilgrastim in the world.

  » Read more